Treatment of Sarcoidosis

Clinics in Chest Medicine

Volumn 29, Issue 3, 2008, Pages 533-548

  Baughman, Robert P ^a   Costabel, Ulrich ^b   du Bois, Ronald M ^c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b RUHRLANDKLINIK   (Germany)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETANERCEPT; FLUTICASONE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; STEROID; TACROLIMUS; THALIDOMIDE;

ANEMIA; BEDTIME DOSAGE; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; EYE TOXICITY; HEMORRHAGIC CYSTITIS; HEPATITIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG FUNCTION TEST; LUNG TOXICITY; NAUSEA; NEOPLASM; NEUTROPENIA; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT CARE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; SARCOIDOSIS; SIDE EFFECT; SOMNOLENCE; TERATOGENESIS; TERATOGENICITY; TREATMENT OUTCOME; WEIGHT GAIN;

COMBINED MODALITY THERAPY; HUMANS; PRACTICE GUIDELINES AS TOPIC; SARCOIDOSIS; TREATMENT OUTCOME;

EID: 44649201234     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2008.03.012     Document Type: Review

References (155)

1. Hunninghake G.W., Costabel U., Ando M., et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 16 (1999) 149-173
2. Baughman R.P., du Bois R.M., and Lower E.E. Sarcoidosis. Lancet 361 (2003) 1111-1118
3. Bradley D.A., Lower E.E., and Baughman R.P. Diagnosis and management of spinal cord sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23 1 (2006) 58-65
4. Neville E., Walker A.N., and James D.G. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 208 (1983) 525-533
5. Baughman R.P., Judson M.A., Teirstein A., et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 99 5 (2006) 307-315
6. Nagai S., Shigematsu M., Hamada K., et al. Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med 5 5 (1999) 293-298
7. Pietinalho A., Furuya K., Yamaguchi E., et al. The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J 13 (1999) 723-726
8. Rizzato G., Fraioli P., and Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax 50 5 (1995) 555-559
9. Sulica R., Teirstein A.S., Kakarla S., et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 128 3 (2005) 1483-1489
10. Baughman R.P., Winget D.B., Bowen E.H., et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis 14 (1997) 154-158
11. Mana J., and Marcoval J. Erythema nodosum. Clin Dermatol 25 3 (2007) 288-294
12. Sharma O.P. Sarcoidosis: a historical perspective. Clin Dermatol 25 3 (2007) 232-241
13. Mana J., Gomez V.C., Montero A., et al. Lofgren's syndrome revisited: a study of 186 patients. Am J Med 107 3 (1999) 240-245
14. Sato H., Grutters J.C., Pantelidis P., et al. HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 27 4 (2002) 406-412
15. Grunewald J., and Eklund A. Sex-specific manifestations of Lofgren's syndrome. Am J Respir Crit Care Med 175 1 (2007) 40-44
16. Baughman R.P., Judson M.A., Teirstein A.S., et al. Thalidomide for chronic sarcoidosis. Chest 122 (2002) 227-232
17. Spiteri M.A., Matthey F., Gordon T., et al. Lupus pernio: a clinico-radiological study of thirty-five cases. Br J Dermatol 112 3 (1985) 315-322
18. Baughman R.P., and Lower E.E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18 (2001) 70-74
19. Chan S.M., Hudson M., and Weis E. Anterior and intermediate uveitis cases referred to a tertiary centre in Alberta. Can J Ophthalmol 42 6 (2007) 860-864
20. Bradley D.A., Baughman R.P., Raymond L., et al. Ocular manifestations of sarcoidosis. Semin Respir Crit Care Med 23 (2002) 543-548
21. Ohara K., Judson M.A., and Baughman R.P. Clinical aspects of ocular sarcoidosis. In: Drent M., and Costabel U. (Eds). Sarcoidosis (2005), The Charlesworth Group, Wakefield (UK) 188-209
22. Baughman R.P., Lower E.E., Bradley D.A., et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 128 2 (2005) 1062-1067
23. Lower E.E., Broderick J.P., Brott T.G., et al. Diagnosis and management of neurologic sarcoidosis. Arch Intern Med 157 (1997) 1864-1868
24. Agbogu B.N., Stern B.J., Sewell C., et al. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 52 (1995) 875-879
25. Deng J.C., Baughman R.P., and Lynch J.P. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med 23 (2002) 513-528
26. Rizzato G., and Colombo P. Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study. Sarcoidosis 13 (1996) 167-172
27. Adams J.S., Diz M.M., and Sharma O.P. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med 111 5 (1989) 437-438
28. Rohatgi P.K. Osseous sarcoidosis. Semin Respir Med 13 (1992) 468-488
29. Gibson G.J., Prescott R.J., Muers M.F., et al. British Thoracic Society Sarcoidosis study: effects of long-term corticosteroid treatment. Thorax 51 3 (1996) 238-247
30. Gottlieb J.E., Israel H.L., Steiner R.M., et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 111 3 (1997) 623-631
31. Hunninghake G.W., Gilbert S., Pueringer R., et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 149 4 Pt 1 (1994) 893-898
32. Rizzato G., Montemurro L., and Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis 15 (1998) 52-58
33. Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 72 1 (1992) 69-71
34. Katoh N., Mihara H., and Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol 147 1 (2002) 154-156
35. Cliff S., Felix R.H., Singh L., et al. The successful treatment of lupus pernio with the flashlamp pulsed dye laser. J Cutan Laser Ther 1 1 (1999) 49-52
36. Baughman R.P., Teirstein A.S., Judson M.A., et al. Clinical characteristics of patients in a case-control study of sarcoidosis. Am J Respir Crit Care Med 164 (2001) 1885-1889
37. Pietinalho A., Tukiainen P., Haahtela T., et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled, multicenter study. Chest 116 (1999) 424-431
38. Pietinalho A., Tukiainen P., Haahtela T., et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 121 (2002) 24-31
39. Alberts C., van der Mark T.W., and Jansen H.M. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 8 5 (1995) 682-688
40. Spiteri M.A., Newman S.P., Clarke S.W., et al. Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sarcoidosis. Eur Respir J 2 3 (1989) 218-224
41. Zych D., Pawlicka L., and Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 10 (1993) 56-61
42. Milman N., Graudal N., Grode G., et al. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 236 3 (1994) 285-290
43. Baughman R.P., Iannuzzi M.C., Lower E.E., et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19 3 (2002) 198-204
44. du Bois R.M., Greenhalgh P.M., Southcott A.M., et al. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 13 6 (1999) 1345-1350
45. Baughman R.P., and Lower E.E. Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol 25 3 (2007) 334-340
46. Siltzbach L.E., and Teirstein A.S. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand 425 (1964) 302S-308S
47. Baughman R.P., and Selroos O. Evidence-based approach to the treatment of sarcoidosis. In: Gibson P.G., Abramson M., and Wood-Baker R. (Eds). Evidence-based respiratory medicine (2005), Blackwell Publishing Ltd., Malden (MA) 491-508
48. Judson M.A. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 115 4 (1999) 1158-1165
49. Baughman R.P., Winget D.B., and Lower E.E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 17 (2000) 60-66
50. Lower E.E., and Baughman R.P. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 155 (1995) 846-851
51. Vucinic V.M. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 8 5 (2002) 470-476
52. Muller-Quernheim J., Kienast K., Held M., et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 14 5 (1999) 1117-1122
53. Lewis S.J., Ainslie G.M., and Bateman E.D. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16 (1999) 87-92
54. Kouba D.J., Mimouni D., Rencic A., et al. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 148 1 (2003) 147-148
55. Baughman R.P., and Lower E.E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 21 (2004) 43-48
56. Kataria Y.P. Chlorambucil in sarcoidosis. Chest 78 (1980) 36-42
57. Baughman R.P., and Lower E.E. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis 14 (1997) 121-130
58. Baughman R.P., Lower E.E., Bradley D.A., et al. Use of cytotoxic therapy for chronic opthalmic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16 (1999) S17
59. Gedalia A., Molina J.F., Ellis G.S., et al. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr 130 (1997) 25-29
60. Kremer J.M., Genovese M.C., Cannon G.W., et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137 9 (2002) 726-733
61. Weinblatt M.E., Kremer J.M., Coblyn J.S., et al. Pharmokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 42 (1999) 1322-1328
62. Chloroquine in the treatment of sarcoidosis. A report from the Research Committee of the British Tuberculosis Association. Tubercle 48 4 (1967) 257-272
63. Jones E., and Callen J.P. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 23 3 Pt 1 (1990) 487-489
64. O'Leary T.J., Jones G., Yip A., et al. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 315 12 (1986) 727-730
65. Baltzan M., Mehta S., Kirkham T.H., et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 160 1 (1999) 192-197
66. Sharma O.P. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurologic involvement. Arch Neurol 55 (1998) 1248-1254
67. Cox C.E., Donohue J.F., Brown C.D., et al. The sarcoidosis health questionnaire. A new measure of health-related quality of life. Am J Respir Crit Care Med 168 (2003) 323-329
68. Benzagmout M., Boujraf S., Gongora-Rivera F., et al. Neurosarcoidosis which manifested as acute hydrocephalus: diagnosis and treatment. Intern Med 46 18 (2007) 1601-1604
69. Baughman R.P., Engel P.J., Meyer C.A., et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23 (2006) 108-116
70. Shorr A.F., Helman D.L., Davies D.B., et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 25 5 (2005) 783-788
71. Baughman R.P., and Lower E.E. Fungal infections as a complication of therapy for sarcoidosis. Q J Med 98 (2005) 451-456
72. Barnes P.J. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 1 3 (2004) 264-268
73. Hew M., Bhavsar P., Torrego A., et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 174 2 (2006) 134-141
74. Goleva E., Hauk P.J., Boguniewicz J., et al. Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J Allergy Clin Immunol 120 5 (2007) 1065-1072
75. Ziegenhagen M.W., Rothe M.E., Zissel G., et al. Exaggerated TNF-alpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2002) 185-190
76. Baughman R.P., and Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17 6 (2003) 425-431
77. Nguyen Y.T., Dupuy A., Cordoliani F., et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 50 2 (2004) 235-241
78. Judson M.A., Silvestri J., Hartung C., et al. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23 1 (2006) 51-57
79. Yee A.M., and Pochapin M.B. Treatment of complicated sarcoidosis with infliximab antitumor necrosis-alpha therapy. Ann Intern Med 135 (2001) 27-31
80. Baughman R.P., Bradley D.A., and Lower E.E. Infliximab for chronic ocular inflammation. Int J Clin Pharmacol Ther 43 (2005) 7-11
81. Doty J.D., Mazur J.E., and Judson M.A. Treatment of sarcoidosis with infliximab. Chest 127 3 (2005) 1064-1071
82. Saleh S., Ghodsian S., Yakimova V., et al. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 100 11 (2006) 2053-2059
83. Sweiss N.J., Welsch M.J., Curran J.J., et al. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum 53 5 (2005) 788-791
84. Baughman R.P., Drent M., Kavuru M., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174 7 (2006) 795-802
85. Rossman M.D., Newman L.S., Baughman R.P., et al. A double-blind, randomized, placebo-controlled trial of infliximab in patients with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23 (2006) 201-208
86. Utz J.P., Limper A.H., Kalra S., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124 1 (2003) 177-185
87. Baughman R.P. Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Reyista Portuguesa de Pneumonologia 13 2 (2007) 547-550
88. Callejas-Rubio J.L., Ortego-Centeno N., Lopez-Perez L., et al. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 25 (2006) 596-597
89. Heffernan M.P., and Smith D.I. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 142 1 (2006) 17-19
90. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 12 (2007) 829-838
91. Paramothayan S., and Jones P.W. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 287 (2002) 1301-1307
92. Paramothayan S., Lasserson T., and Walters E.H. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 3 (2003) CD003536
93. Israel H.L., Fouts D.W., and Beggs R.A. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 107 (1973) 609-614
94. Pietinalho A., Lindholm A., Haahtela T., et al. Inhaled budesonide for treatment of pulmonary sarcoidosis. Results of a double-blind, placebo-controlled, multicentre study. Eur Respir J 9 (1996) 406s
95. Selroos O., and Sellergren T.L. Corticosteroid therapy of pulmonary sarcoidosis. Scand J Respir Dis 60 (1979) 215-221
96. Everhart J.E., Lombardero M., Lake J.R., et al. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 4 4 (1998) 285-296
97. Habib G.S., and Haj S. Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. Clin Rheumatol 24 2 (2005) 129-133
98. Ton F.N., Gunawardene S.C., Lee H., et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20 3 (2005) 464-470
99. Adler R.A., Funkhouser H.L., Petkov V.I., et al. Glucocorticoid-induced osteoporosis in patients with sarcoidosis. Am J Med Sci 325 1 (2003) 1-6
100. Rizzato G., Tosi G., Mella C., et al. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Sarcoidosis 5 2 (1988) 93-98
101. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44 7 (2001) 1496-1503
102. Adler R.A., and Hochberg M.C. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 163 21 (2003) 2619-2624
103. Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax 53 5 (1998) 425-429
104. Sharma O.P. Vitamin D, calcium, and sarcoidosis. Chest 109 2 (1996) 535-539
105. Gallacher S.J., Fenner J.A., Anderson K., et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid-dependent lung disease: an open pilot study. Thorax 47 11 (1992) 932-936
106. Rizzato G., and Montemurro L. Reversibility of exogenous corticosteroid-induced bone loss. Eur Respir J 6 1 (1993) 116-119
107. Gonnelli S., Rottoli P., Cepollaro C., et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 61 5 (1997) 382-385
108. Bartel P.R., Roux P., Robinson E., et al. Visual function and long-term chloroquine treatment. S Afr Med J 84 (1994) 32-34
109. Raiza-Casillas R., Cardenas F., Morales Y., et al. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 13 2 (2004) 119-124
110. Leecharoen S., Wangkaew S., and Louthrenoo W. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus, and scleroderma. J Med Assoc Thai 90 1 (2007) 52-58
111. Yam J.C., and Kwok A.K. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 12 4 (2006) 294-304
112. Marmor M.F., Carr R.E., Easterbrook M., et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 109 7 (2002) 1377-1382
113. Silman A., and Shipley M. Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br J Rheumatol 36 5 (1997) 599-601
114. Baughman R.P., and Lower E.E. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 54 (1999) 742-746
115. Zisman D.A., McCune W.J., Tino G., et al. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 18 3 (2001) 243-252
116. Kremer J.M., Alarcon G.S., Lightfoot Jr. R.W., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 37 3 (1994) 316-328
117. Roenigk H.H., Auerbach R., Maibach H.I., et al. Methotrexate guidelines revised. J Am Acad Dermatol 6 (1982) 145-155
118. Baughman R.P., Weber F.L., Bejarano P.B., et al. Methotrexate for chronic sarcoidosis: hepatotoxicity assessed by liver biopsy. Am J Respir Crit Care Med 159 (1999) A342
119. Demedts M., Behr J., Buhl R., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353 21 (2005) 2229-2242
120. Raghu G., Depaso W.J., Cain K., et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144 2 (1991) 291-296
121. Baughman R.P., and Lower E.E. Steroid-sparing alternative treatments for sarcoidosis. Clin Chest Med 18 (1997) 853-864
122. Mosam A., and Morar N. Recalcitrant cutaneous sarcoidosis: an evidence-based sequential approach. J Dermatolog Treat 15 6 (2004) 353-359
123. Escousse A., Mousson C., Santona L., et al. Azathioprine-induced pancytopenia in homogenous thiopurine methyltransferase-deficient renal transplant recipients: a family study. Transplant Proc 27 (1995) 1739-1742
124. Soria-Royer C., Legendre C., Mircheva J., et al. Thiopurine-methyl-transferase activity to assess azathioprine myelotoxicity in renal transplant recipients. Lancet 341 8860 (1993) 1593-1594
125. Kennedy P.T., Zakaria N., Modawi S.B., et al. Natural history of hepatic sarcoidosis and its response to treatment. Eur J Gastroenterol Hepatol 18 7 (2006) 721-726
126. Osiri M., Shea B., Robinson V., et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and meta analysis. J Rheumatol 30 6 (2003) 1182-1190
127. Emery P., Breedveld F.C., Lemmel E.M., et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39 6 (2000) 655-665
128. Majithia V., Sanders S., Harisdangkul V., et al. Successful treatment of sarcoidosis with leflunomide. Rheumatology (Oxford) 42 5 (2003) 700-702
129. Savage R.L., Highton J., Boyd I.W., et al. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 36 3 (2006) 162-169
130. Chan V., and Tett S.E. How is leflunomide prescribed and used in Australia? Analysis of prescribing and adverse effect reporting. Pharmacoepidemiol Drug Saf 15 7 (2006) 485-493
131. Swigris J.J., Olson A.L., Fischer A., et al. Mycophenolate mofetil is safe, well-tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130 1 (2006) 30-36
132. Zamora A.C., Wolters P.J., Collard H.R., et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102 1 (2008) 150-155
133. Moudgil A., Przygodzki R.M., and Kher K.K. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol 21 2 (2006) 281-285
134. Baughman R.P., Peddi R., and Lower E.E. Therapy: general issues. In: Baughman R.P., du Bois R.M., and Lynch III J.P. (Eds). Diffuse lung disease: a practical approach (2004), Arnold, London 78-90
135. Doty J.D., Mazur J.E., and Judson M.A. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 124 5 (2003) 2023-2026
136. Baughman R.P., and Lower E.E. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 102 4 (1992) 1090-1094
137. Talar-Williams C., Hijazi Y.M., Walther M.M., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124 (1996) 477-484
138. Carlesimo M., Giustini S., Rossi A., et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 32 5 Pt 2 (1995) 866-869
139. Lee J.B., and Koblenzer P.S. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 39 5 Pt 2 (1998) 835-838
140. Baughman R.P., and Lower E.E. Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. Am J Clin Dermatol 5 6 (2004) 385-394
141. Tavares J.L., Wangoo A., Dilworth P., et al. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 91 1 (1997) 31-39
142. Ye Q., Chen B., Tong Z., et al. Thalidomide reduces IL-18, IL-8, and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J 28 4 (2006) 824-831
143. Oliver S.J., Kikuchi T., Krueger J.G., et al. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 102 3 (2002) 225-236
144. Haley H., Cantrell W., and Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 150 1 (2004) 146-149
145. Sollberger M., Fluri F., Baumann T., et al. Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 251 6 (2004) 760-761
146. Kapetanovic M.C., Larsson L., Truedsson L., et al. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 8 4 (2006) R131
147. Kroesen S., Widmer A.F., Tyndall A., et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 42 5 (2003) 617-621
148. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med 345 (2001) 1098-1104
149. Gomez-Reino J.J., Carmona L., and Angel D.M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57 5 (2007) 756-761
150. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 25 (2003) 3133-3140
151. Hansen R.A., Gartlehner G., Powell G.E., et al. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 5 6 (2007) 729-735
152. Wolfe F., and Michaud K. The effect of methotrexate and antitumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56 5 (2007) 1433-1439
153. Almodovar R., Izquierdo M., Zarco P., et al. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 25 1 (2007) 99-101
154. Gonzalez-Lopez M.A., Blanco R., Gonzalez-Vela M.C., et al. Development of sarcoidosis during etanercept therapy. Arthritis Rheum 55 5 (2006) 817-820
155. Sweiss N.J., and Baughman R.P. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon?. J Rheumatol 34 (2007) 2129-2131